US Patent
US9258035 — Multi-mode communication ingestible event markers and systems, and methods of using the same
Formulation · Assigned to Proteus Digital Health Inc · Expires 2029-03-05 · 3y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a device that uses a voltage potential difference to power up an integrated circuit when in contact with a conductive fluid.
USPTO Abstract
A device including an integrated circuit, a partial power source, including first and second materials associated with the integrated circuit is disclosed. The first and second materials are configured to provide a voltage potential difference when in contact with a conductive fluid to power up the device. A signal amplification element secured around the integrated circuit relative to the first and second materials is configured to facilitate extension of a current flow path between the first and second materials. A modulator is configured to control conductance between the first and second materials to generate a detectable signal that is partially defined by the current flow extending through the conductive fluid. A communication module is coupled to the partial power source and is configured to communicate with a receiver and an antenna electrically coupled to the communication module, which uses the antenna to communicate with the receiver.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.